|
|
|
| Effects of Pramipexole combined with Behavioral Therapy on HAMD UPDRS Score Non-motor Symptoms and Quality of Life in Patients with Early-onset Parkinson's Disease and Depression |
| PAN Xiaofeng, et al |
| The First Hospital of Dandong, Liaoning Dandong 118000, China |
|
|
|
|
Abstract Objective: To analyze the effects of pramipexole combined with behavioral therapy on Hamilton depression scale (HAMD), unified Parkinson'sdisease rating scale (UPDRS), non-motor symptoms and quality of life in patients with early-onset Parkinson's disease and depression. Methods: 60 cases of early-onset Parkinson's disease complicated with depression from June 2013 to June 2018 in our hospital were randomly divided into control group treated with pramipexole and combined group treated with pramipexole and behavioral therapy, with 30 cases in each group. The differences of HAMD score and the second and third part of UPDRS scores between the two groups before and 3 months after treatment were compared to assess the degree of depression, non-motor symptoms and quality of life. Results: Compared with before treatment, the HAMD scores of the two groups were significantly decreased at 3 months after treatment (P<0.01); compared with the control group, the HAMD scores of the combined group were significantly decreased at 3 months after treatment (P<0.01). Three months after treatment, the scores of UPDRS in the second part of the two groups were significantly significantly decreased compared with those before treatment, and the score in the combined group was significantly decreased compared with the control group (P<0.01). The scores of UPDRS in the second part of the two groups were significantly decreased compared with those before treatment, and the score in the combined group was significantly decreased compared with the control group (P<0.01). Conclusion: The application of pramipexole combined with behavioral therapy in early-onset Parkinson's disease patients with depression can not only effectively alleviate depression, but also alleviate non-motor symptoms. Therefore, it can promote patients to adjust their mental state, improve their ability of daily living and play an important role in improving their quality of life.
|
|
|
|
|
|
[1] Vanle B, Olcott W, Jimenez J, et al.NMDA antagonists for treating the non-motor symptoms in Parkinson's disease[J].Transl Psychiatry, 2018, 8(1):117.
[2] Randver R.Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex to alleviate depression and cognitive impairment associated with Parkinson's disease: A review and clinical implications[J].Neurol Sci, 2018, 393(1):88~99.
[3] 焦琳娜,章小兵,曹欣,等.盐酸普拉克索对帕金森病合并抑郁患者非运动症状及睡眠质量的影响[J].中国医药导报,2016,13(18):153~156.
[4] 中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版(精神障碍分类)[J].中华精神科杂志,2001,34(3):184~188.
[5] Angel RW, Alston W, Higgins JR. Control of movement in Parkinson's disease[J]. Brain A Neurol, 2015, 93(1):1~14.
[6] Lim J, Bang Y, Choi HJ. Abnormal hippocampal neurogenesis in Parkinson's disease: relevance to a new therapeutic target for depression with Parkinson's disease[J].Arch Pharm Res, 2018, 41(10):943~954.
[7] 张彬彬,候宇,娄伟,等.普拉克索联合多巴丝肼片治疗帕金森病的疗效及对血清BDNF 5-HT NE的影响[J].河北医学,2018,24(8):1297~1301. |
|
|
|
2019, Vol. 25 
